US FDA to hold advisory meeting on Grail's multi-cancer test

• The FDA will use its most stringent review process (premarket approval) for Grail's multi-cancer screening test
• Galleri is designed to detect signals of more than 50 different cancer types from a single blood sample
• The advisory meeting comes after the company reported disappointing clinical trial results

Summary

The U.S. Food and Drug Administration announced it will convene an advisory panel meeting in September to review Grail's multi-cancer screening test, Galleri. The panel will examine Grail's request for premarket approval (PMA), the FDA's most rigorous review process for medical devices, though the agency is not obligated to follow the panel's recommendations.

Key Product Details:

Galleri is a blood-based cancer screening test designed to detect signals from more than 50 different types of cancer using a single blood sample. This multi-cancer early detection approach represents a significant potential advancement in cancer screening technology.

Context:

The review comes following disappointing clinical trial results from Grail, though specific details of these results were not elaborated in the announcement. This background suggests the advisory panel meeting may involve careful scrutiny of the test's efficacy and clinical validity.

Market Impact:

News of the FDA advisory meeting sent Grail's stock higher on Friday, indicating investor optimism that regulatory review could advance despite previous setbacks. The September timeline provides a concrete date for potential regulatory progress.

Regulatory Significance:

The premarket approval pathway indicates the FDA is treating Galleri as a high-risk device requiring extensive clinical evidence. Advisory committee meetings typically signal the agency is seriously evaluating an application but seeks independent expert input on complex scientific or clinical questions. While advisory panel recommendations are non-binding, they often influence final FDA decisions and can significantly impact market expectations for approval prospects.

The outcome of this meeting will be closely watched by investors and the broader oncology community as a potential milestone for multi-cancer early detection technology.